You just read:

G3 Pharmaceuticals Signs Exclusive License and Option Agreement for Treating Diastolic Heart Failure (HFpEF) by Inhibiting Galectin-3.

News provided by

G3 Pharmaceuticals

Oct 30, 2018, 10:00 ET